Navigation Links
Asymmetrex Approved to Conduct an ASTM Interlaboratory Evaluation of Its AlphaSTEM Test™ Technology as a Standard for Counting Therapeutic Adult Tissue Stem Cells
Date:5/21/2019

At their May 16 meeting, the members of the F04.43 Subcommittee on Cells and Tissue Engineered Constructs for Tissue Engineered Medical Products (TEMPs) of the American Society for Testing and Materials International voted unanimously to approve an interlaboratory study proposed by Asymmetrex. Gaining this approval was the next step in the company’s plan to establish its AlphaSTEM Test™ stem cell counting technology as a standard for stem cell medicine.

ASTM International is a 121 year-old organization that was founded and exists to improve and assure the quality of diverse industry manufactured products. It accomplishes this mission by developing worldwide consensus standards for industrial testing and industrial materials. Though founded on standards for factory operations and building materials, its purview now extends well beyond to standards for products like those covered by the F04.43 Subcommittee, including TEMPs and now therapeutic tissue stem cells.

The approval for Asymmetrex is very timely for the stem cell medicine industry. One day earlier on May 15, the Standards Coordinating Body released a working draft of its new report that identifies new standards needed for regenerative medicine. The SCB is an FDA-contracted agency with the mission of complementing the existing processes of standard development organizations like ASTM by engaging regenerative medicine stakeholders to ensure that new or revised standards provide the greatest benefits to the broad regenerative medicine community. One of the needed standards introduced in the draft report is a standard for specific counting of tissue stem cells investigated in stem cell therapy clinical trials.

Asymmetrex director James Sherley observes that, “the incorporation of standards need C20 on page 51 of the new report is an excellent example of evidence that the SCB is already achieving its mission of improving progress in regenerative medicine. Identifying and acknowledging fundamental knowledge and technological gaps will motivate ingenuity in scientific discovery and engineering.”

About Asymmetrex

Asymmetrex, LLC is a Massachusetts life sciences company with a focus on developing technologies to advance stem cell medicine. Asymmetrex’s founder and director, James L. Sherley, M.D., Ph.D. is an internationally recognized expert on the unique properties of adult tissue stem cells. The company’s patent portfolio contains biotechnologies that solve the two main technical problems – production and quantification – that have stood in the way of successful commercialization of human adult tissue stem cells for regenerative medicine and drug development. In addition, the portfolio includes novel technologies for isolating cancer stem cells and producing induced pluripotent stem cells for disease research purposes. Asymmetrex markets the first technology for determination of the dose and quality of tissue stem cell preparations (the “AlphaSTEM Test™”) for use in stem cell transplantation therapies and pre-clinical drug evaluations

Read the full story at https://www.prweb.com/releases/asymmetrex_approved_to_conduct_an_astm_interlaboratory_evaluation_of_its_alphastem_test_technology_as_a_standard_for_counting_therapeutic_adult_tissue_stem_cells/prweb16325709.htm.


'/>"/>
Source: PRWeb
Copyright©2019 Vocus, Inc.
All rights reserved


Related biology news :

1. Asymmetrex Presents Proposal for ASTM Interlaboratory Evaluation of AlphaSTEM Test™ Technology Towards Establishing A Standard for Counting Therapeutic Stem Cells
2. Asymmetrex Publishes Chapter Explaining the Critical Need for Stem Cell Dosing for Success in Stem Cell Medicine
3. Asymmetrex Suggests a Stemgene Relief from Recent Cancer Woes About CRISPR-Cas9 Gene-Editing Therapies
4. Asymmetrex Proposes “Stemgene Therapy” to Emphasize the Importance of Tissue Stem Cells for Successful Gene Therapy
5. TGen and NAU patent for new pandemic flu test is approved
6. Nxt-ID Approved for NASDAQ Capital Market Listing
7. FDA-approved drug restores hair in patients with Alopecia Areata
8. Drug design success propels efforts to fight HIV with a combination of 2 FDA-approved drugs
9. New telemetry implants expected to change how large animal toxicology studies are conducted
10. Marvin Test Solutions Brings New Capabilities to PXI-Based Semiconductor Test with TS-960
11. UCSB researchers develop ultra sensitive biosensor from molybdenite semiconductor
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/4/2019)... MEMPHIS, Tenn. (PRWEB) , ... June 04, 2019 ... ... in contract manufacturing of orthopedic medical devices, today announced Q1-19 revenues of $31M, ... the industry combined with successful roll-out of strategic investments & operational excellence initiatives ...
(Date:6/4/2019)... ... , ... Most preclinical EEG visualization platforms offer tools intended ... on variations of amplitude, frequency or spike train detection. In the clinic, however, ... complexity and variability of the signal, and automation tools are used only in ...
(Date:6/1/2019)... FREDERICK, Md. (PRWEB) , ... May 31, 2019 ... ... legal firm Wilson Sonsini Goodrich & Rosati recently invested in BioFactura’s $6M Series ... WSGR, BioFactura is now securing value-added institutional investors who bring significant financial and ...
Breaking Biology News(10 mins):
(Date:6/11/2019)... ... June 11, 2019 , ... A study released today in ... are able to incorporate into human CD34+ cells, modifying their gene expression and ... increased the cells’ ability to lodge into bone marrow. This research performed by ...
(Date:5/31/2019)... ... May 29, 2019 , ... ... from the USPTO providing proprietary interest to our methodology, processes, and diagnostic ... DIAGNOSIS AND TREATMENT… extends Somnology’s IP rights including our proprietary sleep scoring ...
(Date:5/31/2019)... ... May 30, 2019 , ... A study released today in ... for the sustained release of human placental stem cell (HPSC)-derived conditioned medium (CM) ... deliver CM into the injured kidney, where it helped restore function and regenerate ...
(Date:5/15/2019)... , ... May 15, 2019 , ... Milton Hershey School® ... recognition for his work within the biomedical industry, where he is changing lives by ... devices. , “William Harding epitomizes the vision of our founders – Milton and ...
Breaking Biology Technology: